deltatrials

Ovarian endometrioid adenocarcinoma Trials in Seattle, United States

Conditions / Ovarian endometrioid adenocarcinoma / Seattle, United States

Clinical trials for Ovarian endometrioid adenocarcinoma investigate a range of treatment strategies and patient populations.

14 total trials for this combination

Showing top 10 of 14 trials

Trials

NCT ID Title Status Phase
NCT00719303 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer UNKNOWN PHASE3
NCT01167712 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer ACTIVE_NOT_RECRUITING PHASE3
NCT02502266 Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer ACTIVE_NOT_RECRUITING
NCT02502266 Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer ACTIVE_NOT_RECRUITING
NCT02502266 Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer ACTIVE_NOT_RECRUITING
NCT02502266 Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer ACTIVE_NOT_RECRUITING
NCT00262847 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer COMPLETED PHASE3
NCT00951496 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer COMPLETED PHASE3
NCT02502266 Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer ACTIVE_NOT_RECRUITING
NCT02502266 Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer ACTIVE_NOT_RECRUITING

Related Pages